MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    Identifying Subjects with Dopamine Transporter Deficit in a Population-based Recruitment Strategy: Kassel Data of Healthy Brain Ageing

    S. Schade, K. Rege, C. Corinne, A. Garrido, T. Marques, P. Mahlknecht, S. Ghosh, R. Rawal, C. Pauly, T. Wicke, E. Lang, S. Schnell, S. Scaglione, H. Hakelberg, V. Satagopam, M. Marti, E. Tolosa, W. Poewe, R. Krüger, C. Trenkwalder, B. Mollenhauer, D. Pilco (Kassel, Germany)

    Objective: To identify subjects with dopamine transporter (DaT) deficit being at high risk for prodromal PD. Background: Neurodegeneration and dopaminergic deficit in PD occur before the development…
  • 2024 International Congress

    Rationale and Design of the Slowing Parkinson’s Early through Exercise Dosage – United Kingdom (Slow-SPEED-UK) Trial

    E. Mitchell (London, United Kingdom)

    Objective: Slow-SPEED-UK is a randomized controlled trial investigating the effects of an app-based exercise program on individuals at higher risk of Parkinson’s Disease (PD). Background:…
  • 2024 International Congress

    Non-interventional phase 0 study for the collection of biospecimens from patients with Parkinson’s Disease (PD) to support the development of a diagnostic classifier for LRRK2-driven PD

    L. Desnoyers, S. Dheerendra, C. Wong, T. Dang, S. Esmaeeli, M. van Derbrug, M. Nalls, A. Ellenbogen, S. Jackson (South San Francisco, USA)

    Objective: Measure LRRK2 pathway activity in Parkinson’s Disease patients stratified using a genetic predictive classifier model. Background: Extensive research has shown that overactivation of the…
  • 2024 International Congress

    Improvement in Uninterrupted Good ON Time and Reduction in OFF Periods with CSAI Treatment

    D. Kremens, R. Hauser, A. Formella, M. Joshi, M. Grall (Philadelphia, USA)

    Objective: Evaluate the effect of continuous subcutaneous apomorphine infusion (CSAI) on daily periods of OFF time and Good ON time (ON without troublesome dyskinesia) in…
  • 2024 International Congress

    Blautia argi ameliorates the motor impairment of 6-Hydroxydopamine hydrochloride-induced Parkinson’s disease rat model

    G. Tian, R. Zhou, J. Lu, W. Shi, R. Li, X. Guo (Xi'an, China)

    Objective: To evaluate the potential protective effects of Blautia argi on a 6-Hydroxydopamine (6-OHDA)-induced rat model of Parkinson's disease (PD). Background: PD is a common…
  • 2024 International Congress

    Continuous Dopaminergic Stimulation-based Levodopa Treatment in Early to Mid-stage Parkinson’s Disease Patients: A Systematic Review and Meta-analysis

    R. Tang, R. Sun, S. Zhang, L. Chen (Shanghai, China)

    Objective: To compare the clinical effectiveness between continuous dopaminergic stimulation (CDS)-based and intermittent levodopa (IL) treatment in patients with early to mid-stage Parkinson’s disease (PD).…
  • 2024 International Congress

    Motor Impact of Fasting in Parkinson’s Disease Patients: An overview

    N. Kouki, M. Messelmani, N. Kouki, H. Derbali, J. Zaouali, R. Mrissa (tunis, Tunisia)

    Objective: To provide a literature overview of fasting impact  on motor symptoms in Parkinson disease. Background: Fasting, characterized by voluntary abstinence from food and caloric…
  • 2024 International Congress

    Comparative analysis of opicapone and entacapone in the management of motor fluctuations in patients with Parkinson’s disease, from clinical trials to healthcare resource usage

    D. Kremens, F. Amjad, S. Thakkar, B. Naderi, D. Martins, J. Rocha, G. Banisadr, S. Fisher (Wynnewood, USA)

    Objective: To assess the differences between two catechol-O-methyltransferase (COMT) inhibitors, opicapone (OPC) and entacapone (ENT). Background: Opicapone and ENT are COMT inhibitors developed as adjunct…
  • 2024 International Congress

    Multicenter study of efficacy and safety of subcutaneous foslevodopa/foscarbidopa treatment initiation or switch from LD/CD intestinal gel

    M. Morales-Casado, G. Tabar-Comellas, E. Gisbert-Tijeras, DD. García-Meléndez, J. Domínguez-Bértalo, D. Rivero-Rodríguez, N. López-Ariztegui (Toledo, Spain)

    Objective: To describe a series of patients under treatment with subcutaneous foslevodopa/foscarbidopa, either as initiation therapy or after switching from intestinal levodopa/carbidopa. Background: Treatment with…
  • 2024 International Congress

    Studying digenic Parkinson’s disease in a stem cell model carrying mutant p.N409S in the GBA1 gene and the homozygous deletion of exon 3 PARK2

    C. Oleksy, Z. Hanss, F. Massart, G. Arena, I. Boussaad, R. Krüger (Belvaux, Luxembourg)

    Objective: We aim to study the combined effect of the GBA1 p.N409S mutation and a complete loss of Parkin based on a patient-based stem cell…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley